Assessing the effect of caffeine on attention in patients with and without dementia

Not Applicable

Completed

• Conditions: Dementia; Dementia with Lewy bodies, Parkinson's disease dementia, Alzheimer's dementia, vascular dementia, frontotemporal lobe dementia; Mental and Behavioural Disorders

• Registration Number: ISRCTN78129879
• Lead Sponsor: orth Bristol NHS Trust (UK)

Brief Summary

2016 results presented at ABN Annual Meeting 2016 https://jnnp.bmj.com/content/87/12/e1.201

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-06-06
• Study Completion: 2018-07-01
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Patients with dementia with Lewy bodies or Parkinson's disease dementia fulfilling standard diagnostic criteria who retain capacity to consent to research, in keeping with the Mental Capacity Act 2005
2. Patients on or off cholinesterase inhibitors or memantine as long as stable on medication for 3 months or more
3. An adequate level of communication in written and verbal English

Exclusion Criteria

1. Patients with alternative neurodegenerative diseases or other condition likely to interfere with test performance (e.g. chronic pain, stroke)
2. Patients on medication likely to interfere with cognitive performance that has been changed in the last 3 months
3. The tests of attention in this trial require a working knowledge of English, good vision and the ability to walk independently (with or without walking aids) and we will therefore exclude patients without sufficient English language skills, those with poor vision and those who cannot walk independently.
4. Patients taking caffeine containing medication or foodstuffs with greater than 15mg caffeine over a day who do not wish to cease ingestion
5. If a patient loses capacity to consent during the trial they will be withdrawn

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Attention, measured by neuropsychological tests

Secondary Outcome Measures

Name	Time	Method
<br> 1. Ability to complete a timed walk<br> 2. Ability to complete a timed walking while talking task<br> 3. The measure of habitual caffeine intake by patients with dementia and its correlation with hallucinations and sleeping patterns<br>